Table 1.
Characteristics of the overall study population and stratification by HIV-1 DNA level at week 96
| Variables | Total (N = 69) | Group 1 (N = 21) | Group 2 (N = 48) | P value |
|---|---|---|---|---|
| Sex | 0.082 | |||
| Male | 43 (62.3%) | 10 (47.6%) | 33 (68.8%) | |
| Female | 26 (37.7%) | 11 (52.4%) | 15 (31.2%) | |
| Age (years) | 33 (27–39) | 33 (29–41) | 33 (27–38) | 0.396 |
| Time from diagnosis to ART (months) | 7.7 (1.1–25.5) | 6.0 (1.0–16.0) | 9.0 (1.2–28.0) | 0.556 |
| HIV-1 subtype | 0.422 | |||
| AE | 21 (30.4%) | 5 (23.8%) | 16 (33.3%) | |
| B/C/BC | 19 (27.5%) | 6 (28.6%) | 13 (27.1%) | |
| Not known | 29 (42.1%) | 10 (47.6%) | 19 (39.6%) | |
| ART therapy | 0.332 | |||
| AZT/d4T + 3TC + NVP | 19 (27.5%) | 7 (33.3%) | 12 (25.0%) | |
| TDF + 3TC + EFV | 50 (72.5%) | 14 (66.7%) | 36 (75.0%) | |
| Pre-ART HIV-1 DNA (log10 copies/106 PBMCs), median (IQR), |
2.0 (1.7–2.2) | 1.8 (1.5–2.4) | 2.0 (1.8–2.2) | 0.379 |
| Pre-ART plasma viral load (log10 copies/mL), median (IQR) |
4.1 (3.6–4.5) | 4.0 (3.6–4.4) | 4.2 (3.7–4.6) | 0.445 |
| Pre-ART CD4+ T-cell count (cells/μL), median (IQR) | 305 (256–385) | 305 (274–412) | 306 (232–378) | 0.312 |
| Nadir CD4+ T-cell count (cells/μL), median (IQR) | 292 (245–357) | 295 (271–374) | 291 (224–350) | 0.240 |
| Pre-ART CD8+ T-cell count (cells/μL), median (IQR) | 845 (614–1073) | 859 (634–1114) | 763 (607–1074) | 0.907 |
| Pre-ART CD4/CD8 ratio, median (IQR) | 0.35 (0.27–0.51) | 0.42 (0.29–0.51) | 0.34 (0.24–0.49) | 0.180 |
| HIV-1 DNA after 2 years’ ART (log10 copies/106 PBMCs), median (IQR) |
1.7 (1.3–2.0) | 1.3 (1.3–1.3) | 1.9 (1.6–2.4) | <0.001 |
ART Antiretroviral therapy, PBMCs Peripheral blood mononuclear cells, IQR Inter-quartile range